Newsletter |
|
CRASH-2
Recruitment achievement 5000 patients!
|
|
Congratulations to you all for continuing to work tirelessly for the success of your trial. By the time you receive this letter the trial will have recruited over 5000 patients. This is due purely to the hard work and dedication of all our collaborators. The recruitment plan made at the start of the trial is shown in the graph in red. As you can see (in blue) we have achieved consistently above this prediction. However, we have now hit the hardest phase and need to step up recruitment even more. Congratulations to you all again for achieving this important milestone! |
![]() |
![]() |
NEW COCHRANE SYSTEMATIC REVIEW: What are the effects of administration of Recombinant factor VIIa for managing haemorrhage in patients without haemophilia? |
![]() |
Recombinant factor VIIa (rFVIIa) is increasingly being used off-license to prevent bleeding in operations where blood loss is likely to be high, and/or stopping bleeding that is proving difficult to control by other means. A new Cochrane Systematic Review1 examines the evidence from randomised controlled trials (RCTs) for the effects of such prophylactic and therapeutic use of rFVIIa in these indications. The authors found 13 placebo-controlled double-blind RCTs eligible for inclusion; six (n=724) examined the prophylactic use of rFVIIa and seven (n=1214) the therapeutic use. For both uses the data from the studies suggest there is no observed advantage or disadvantage of using rFVIIa over placebo that could not have been a result of chance alone. The review concluded that whilst rFVIIa has a role in the management of patients with haemophilia, its effectiveness as a more general haemostatic drug remains uncertain. The use of rFVIIa outside its current licensed indications should be very limited and its wider use should await the results of ongoing and possibly newly commissioned RCTs. In the interim, rFVIIa use should be restricted to clinical trials. The full text of the review can be accessed through The Cochrane Library (www.thecochranelibrary.com). For more information about the Cochrane Injuries Group and to access abstracts of other systematic reviews, please visit www.cochrane-injuries.lshtm.ac.uk. 1Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD005011. DOI: 10.1002/14651858.CD005011.pub2. |
crash 2 around the world |
|
|
Abdelazeem Eldawlatly and team in King Khalid University Hospital, Saudi Arabia |
Rasananda
Mangual and team in MKCG Medical College, India
|
![]() |
Silvana Svampa and team in Hospital Castro Rendon, Argentina |
Jorge Teves and team in Hospital Dr Oscar Alende, Argentina |
![]() |
|
P V Ramana and team in Care Hospital, India |
new
faces
|
|||
Matthew
Berle started as a Trial Assistant in April and will be working with
the admin team preparing the trial materials.
|
![]() |
We welcome to the trial team Juan Camilo Correa, a 5th year medical student, who will be looking after all the data from Hospital Universitario San Vicente de Paul in Colombia. |
first patient - Randomisation has started in the following centres:
new ethics approvals - Welcome to the trial:
Background
image: Hospital Universitario San Vicente de Paul, Colombia
|